{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:40:34Z","timestamp":1776274834850,"version":"3.50.1"},"reference-count":66,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"unspecified","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Project-ID 422744262 - TRR 289"],"award-info":[{"award-number":["Project-ID 422744262 - TRR 289"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psoriasis is a chronic inflammatory skin disease that significantly impacts patients\u2019 quality of life. Although biological therapies are effective, they are associated with high costs and potential side effects, necessitating strategies for dose reduction. Pharmacological conditioning, using placebo mechanisms through associative learning, presents a promising approach to maintain therapeutic efficacy with lower doses of medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The single-centre, randomised controlled trial aims to investigate pharmacological conditioning with secukinumab in patients with moderate-to-severe psoriasis (N=168). Participants will be randomly allocated to a treatment-as-usual group or one of two experimental groups receiving partial or continuous reinforcement schedules with reduced secukinumab doses combined with a distinctive gustatory stimulus. Primary outcomes include changes in itch intensity, skin-related quality of life and objective disease severity. Secondary outcomes encompass psychological variables, side effects and biological markers. Results may contribute to optimised long-term psoriasis management, reducing medication burden while maintaining treatment efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol was approved by the ethics committee of the University Hospital Essen (19\u20138636 BO) on 20 November 2023. Written informed consent will be obtained from all participants. Participant confidentiality will be ensured through pseudonymised data handling and secure storage. The results will be disseminated through peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>DRKS00034977.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-114026","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:40:53Z","timestamp":1776271253000},"page":"e114026","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Study protocol for testing pharmacological conditioning as a drug dose reduction strategy in patients with psoriasis in a randomised controlled trial"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5969-207X","authenticated-orcid":false,"given":"Paraskevi","family":"Savvidou","sequence":"first","affiliation":[{"name":"University of Duisburg-Essen, Institute for Medical Education, Center for Translational and Behavioral Neurosciences, University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"H\u00f6lsken","sequence":"additional","affiliation":[{"name":"University of Duisburg-Essen, Institute for Medical Education, Center for Translational and Behavioral Neurosciences, University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Krefting","sequence":"additional","affiliation":[{"name":"University of Duisburg-Essen, Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4487-4258","authenticated-orcid":false,"given":"Sven","family":"Benson","sequence":"additional","affiliation":[{"name":"University of Duisburg-Essen, Institute for Medical Education, Center for Translational and Behavioral Neurosciences, University Hospital Essen, Essen, Germany"},{"name":"University of Duisburg-Essen, Institute of Medical Psychology and Behavioral Immunobiology, Center for Translational and Behavioral Neurosciences, University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3684-3523","authenticated-orcid":false,"given":"Wiebke","family":"Sondermann","sequence":"additional","affiliation":[{"name":"University of Duisburg-Essen, Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany"},{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026041509402943000_16.4.e114026.1","first-page":"25","article-title":"Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician","volume":"12","author":"Blackstone","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"2026041509402943000_16.4.e114026.2","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v101.565","article-title":"Common Fundamentals of Psoriasis and Depression","volume":"101","author":"H\u00f6lsken","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2026041509402943000_16.4.e114026.3","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01060-5"},{"key":"2026041509402943000_16.4.e114026.4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.09110.x"},{"key":"2026041509402943000_16.4.e114026.5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026041509402943000_16.4.e114026.6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ard.2025.01.006","article-title":"Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics","volume":"84","author":"Gisondi","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026041509402943000_16.4.e114026.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1593-8"},{"key":"2026041509402943000_16.4.e114026.8","first-page":"411","article-title":"Adverse drug reactions to biologics","volume":"8","author":"Scherer","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026041509402943000_16.4.e114026.9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026041509402943000_16.4.e114026.10","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12817","article-title":"Injection site reactions with the use of biological agents","volume":"32","author":"Thomaidou","year":"2019","journal-title":"Dermatol Ther"},{"key":"2026041509402943000_16.4.e114026.11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1369805","article-title":"Dose reduction of biologics in patients with plaque psoriasis: a review","volume":"15","author":"van Riel","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026041509402943000_16.4.e114026.12","first-page":"349","article-title":"Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review","volume":"81","author":"Michielsens","year":"2021","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026041509402943000_16.4.e114026.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2011.12.001"},{"key":"2026041509402943000_16.4.e114026.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1907805"},{"key":"2026041509402943000_16.4.e114026.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3923"},{"key":"2026041509402943000_16.4.e114026.16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/exd.13158","article-title":"Using the placebo effect: how expectations and learned immune function can optimize dermatological treatments","volume":"26","author":"Evers","year":"2017","journal-title":"Exp Dermatol"},{"key":"2026041509402943000_16.4.e114026.17","doi-asserted-by":"publisher","DOI":"10.1159\/000490354"},{"key":"2026041509402943000_16.4.e114026.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEjMp1504023"},{"key":"2026041509402943000_16.4.e114026.19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.2025.6261","article-title":"Improving Patients\u2019 Treatment Expectations","volume":"334","author":"Laferton","year":"2025","journal-title":"JAMA"},{"key":"2026041509402943000_16.4.e114026.20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1159\/000513445","article-title":"Effects of Patients\u2019 Expectation in Dermatology: Evidence from Experimental and Clinical Placebo Studies and Implications for Dermatologic Practice and Research","volume":"237","author":"Sondermann","year":"2021","journal-title":"Dermatology"},{"key":"2026041509402943000_16.4.e114026.21","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/jid.2014.522","article-title":"Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions","volume":"135","author":"van Laarhoven","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2026041509402943000_16.4.e114026.22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CCID.S4465","article-title":"Itch in psoriasis: epidemiology, clinical aspects and treatment options","volume":"2","author":"Prignano","year":"2009","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026041509402943000_16.4.e114026.23","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jid.2019.05.034","article-title":"Itch and Mental Health in Dermatological Patients across Europe: A Cross-Sectional Study in 13 Countries","volume":"140","author":"Dalgard","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2026041509402943000_16.4.e114026.24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/exd.14071","article-title":"Role of neuroimmune circuits and pruritus in psoriasis","volume":"29","author":"Ayasse","year":"2020","journal-title":"Exp Dermatol"},{"key":"2026041509402943000_16.4.e114026.25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020669","article-title":"The Brain-Skin Axis in Psoriasis-Psychological, Psychiatric, Hormonal, and Dermatological Aspects","volume":"23","author":"Marek-Jozefowicz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026041509402943000_16.4.e114026.26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/ijd.14678","article-title":"Pain and Pruritus: a study of their similarities and differences","volume":"59","author":"Anzelc","year":"2020","journal-title":"Int J Dermatol"},{"key":"2026041509402943000_16.4.e114026.27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/exd.13232","article-title":"Placebo and nocebo effects as major components of the treatment of itch","volume":"26","author":"Misery","year":"2017","journal-title":"Exp Dermatol"},{"key":"2026041509402943000_16.4.e114026.28","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2015.00057","article-title":"Contagious itch: what we know and what we would like to know","volume":"9","author":"Schut","year":"2015","journal-title":"Front Hum Neurosci"},{"key":"2026041509402943000_16.4.e114026.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2015.01.011"},{"key":"2026041509402943000_16.4.e114026.30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2340\/00015555-2823","article-title":"Placebo Effects of Open-label Verbal Suggestions on Itch","volume":"98","author":"Meeuwis","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2026041509402943000_16.4.e114026.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.01.043"},{"key":"2026041509402943000_16.4.e114026.32","first-page":"370","article-title":"Classical conditioning in the treatment of psoriasis","volume":"35","author":"Ader","year":"2000","journal-title":"Integr Physiol Behav Sci"},{"key":"2026041509402943000_16.4.e114026.33","first-page":"9","article-title":"Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients","volume":"15","author":"H\u00f6lsken","year":"2025","journal-title":"Psoriasis (Auckl)"},{"key":"2026041509402943000_16.4.e114026.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.03.002"},{"key":"2026041509402943000_16.4.e114026.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2006.04.005"},{"key":"2026041509402943000_16.4.e114026.36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/j.pain.0000000000002820","article-title":"Placebo effects on cutaneous pain and itch: a systematic review and meta-analysis of experimental results and methodology","volume":"164","author":"Blythe","year":"2023","journal-title":"Pain"},{"key":"2026041509402943000_16.4.e114026.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2006.08.025"},{"key":"2026041509402943000_16.4.e114026.38","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0b013e3181cbd38b"},{"key":"2026041509402943000_16.4.e114026.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2007.05.016"},{"key":"2026041509402943000_16.4.e114026.40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7072.1624"},{"key":"2026041509402943000_16.4.e114026.41","doi-asserted-by":"publisher","DOI":"10.1177\/014107689909201005"},{"key":"2026041509402943000_16.4.e114026.42","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0389com"},{"key":"2026041509402943000_16.4.e114026.43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004589","article-title":"SPIRIT 2025 statement: Updated guideline for protocols of randomised trials","volume":"22","author":"Chan","year":"2025","journal-title":"PLoS Med"},{"key":"2026041509402943000_16.4.e114026.44","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026041509402943000_16.4.e114026.45","doi-asserted-by":"crossref","first-page":"101522","DOI":"10.1016\/j.softx.2023.101522","article-title":"ALIIAS: Anonymization\/Pseudonymization with LimeSurvey integration and II-factor Authentication for Scientific research","volume":"24","author":"Englert","year":"2023","journal-title":"SoftwareX"},{"key":"2026041509402943000_16.4.e114026.46","unstructured":"LimeSurvey GmbH . LimeSurvey: an open source survey tool. Hamburg, Germany, 2025. Available: https:\/\/www.limesurvey.org"},{"key":"2026041509402943000_16.4.e114026.47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"2026041509402943000_16.4.e114026.48","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"2026041509402943000_16.4.e114026.49","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2023.1182175","article-title":"m-Path: an easy-to-use and highly tailorable platform for ecological momentary assessment and intervention in behavioral research and clinical practice","volume":"5","author":"Mestdagh","year":"2023","journal-title":"Front Digit Health"},{"key":"2026041509402943000_16.4.e114026.50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00403-012-1256-y","article-title":"Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis","volume":"304","author":"Feuerhahn","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"2026041509402943000_16.4.e114026.51","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.865009"},{"key":"2026041509402943000_16.4.e114026.52","unstructured":"Spielberger C . Manual for the State-Trait Anxiety Inventory (STAI). Palo Alto, CA: Consulting Psychologists Press, 1970."},{"key":"2026041509402943000_16.4.e114026.53","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-006-2098-7"},{"key":"2026041509402943000_16.4.e114026.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jrp.2006.02.001"},{"key":"2026041509402943000_16.4.e114026.55","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2067"},{"key":"2026041509402943000_16.4.e114026.56","unstructured":"Rief W , Nestoriuc Y , Mueller EM , et al . Generic rating scale for previous treatment experiences, treatment expectations, and treatment effects (GEEE). PsychArchives 2021. doi:10.23668\/PSYCHARCHIVES.4717"},{"key":"2026041509402943000_16.4.e114026.57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/PSY.0000000000001038","article-title":"The Interoceptive Sensitivity and Attention Questionnaire: Evaluating Aspects of Self-Reported Interoception in Patients With Persistent Somatic Symptoms, Stress-Related Syndromes, and Healthy Controls","volume":"84","author":"Bogaerts","year":"2022","journal-title":"Psychosom Med"},{"key":"2026041509402943000_16.4.e114026.58","unstructured":"Dillmann U , Nilges P , Saile H , et al . PDI - Pain Disability Index - deutsche Fassung [Verfahrensdokumentation und Fragebogen]. Open Test Archive. Trier: Leibniz-Institut f\u00fcr Psychologie (ZPID). 2011. doi:10.23668\/psycharchives.4505"},{"key":"2026041509402943000_16.4.e114026.59","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-016-0875-9","article-title":"The German version of the Perceived Stress Scale - psychometric characteristics in a representative German community sample","volume":"16","author":"Klein","year":"2016","journal-title":"BMC Psychiatry"},{"key":"2026041509402943000_16.4.e114026.60","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(90)90004-A"},{"key":"2026041509402943000_16.4.e114026.61","unstructured":"Laux L , Hock M , Bergner-K\u00f6ther R , et al . Das State-Trait-Angst-Depressions-Inventar: STADI; Manual. G\u00f6ttingen: Hogrefe, 2013."},{"key":"2026041509402943000_16.4.e114026.62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0280472","article-title":"The Treatment Expectation Questionnaire (TEX-Q): Validation of a generic multidimensional scale measuring patients\u2019 treatment expectations","volume":"18","author":"Shedden-Mora","year":"2023","journal-title":"PLoS One"},{"key":"2026041509402943000_16.4.e114026.63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/21677026221094331","article-title":"How to Change Negative Outcome Expectations in Psychotherapy? The Role of the Therapist\u2019s Warmth and Competence","volume":"11","author":"Seewald","year":"2023","journal-title":"Clin Psychol Sci"},{"key":"2026041509402943000_16.4.e114026.64","unstructured":"R Core Team . R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2021. Available: https:\/\/www.R-project.org"},{"key":"2026041509402943000_16.4.e114026.65","unstructured":"RStudio Team . RStudio: Integrated development environment for R. Boston, MA: RStudio, 2021. Available: https:\/\/posit.co"},{"key":"2026041509402943000_16.4.e114026.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2007.01.008"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-114026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:41:00Z","timestamp":1776271260000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-114026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":66,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,15]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjopen-2025-114026"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-114026","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}